Real-world cost-effectiveness of cetuximab in the third-line treatment of metastatic colorectal cancer based on patient chart review in the Netherlands

OBJECTIVE: To assess the cost effectiveness of cetuximab in third-line treatment of patients with KRAS wild-type (wt) metastatic colorectal cancer (mCRC) in routine clinical practice compared with best supportive care (BSC). METHODS: Patients (n = 287) with KRAS wt mCRC treated with cetuximab or BSC...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Health Econ Rev
Autori principali: Uyl-de Groot, Carin A., van Rooijen, Elisabeth M., Punt, Cornelis J. A., Pescott, Chris P.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer Berlin Heidelberg 2018
Soggetti:
Review
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6049844/
https://ncbi.nlm.nih.gov/pubmed/30019286
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13561-018-0197-3
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi